Covid-19 vaccine: ‘At least 50 per cent efficacy’, DCGI issues new guidelines | Latest News India - Hindustan Times
close_game
close_game

Covid-19 vaccine: ‘At least 50 per cent efficacy’, DCGI issues new guidelines

Hindustan Times, New Delhi | Byhindustantimes.com | Edited by Poulomi Ghosh
Sep 23, 2020 08:44 AM IST

Study pregnant women for whom the date of conception is prior to vaccination or within 30 days after vaccination, DCGI mentions in its Covid-19 vaccine guideline

On the lines of the World Health Organization (WHO) and the US Food and Drug Administration (US FDA), the Drugs Controller General of India (DCGI) has issued a new set of guidelines for Covid-19 vaccine candidates, focussing on safety, immunogenicity and efficacy parameters.

DCGI has asked pharma companies to keep pregnant women and women of child-bearing age in mind as they are rolling out trials of Covid-19 vaccines.(PTI)
DCGI has asked pharma companies to keep pregnant women and women of child-bearing age in mind as they are rolling out trials of Covid-19 vaccines.(PTI)

According to the guideline, a Covid-19 vaccine candidate should have at least 50 per cent of efficacy in the Phase-3 clinical trial for it to be widely deployed. Additionally, the pharma companies developing the vaccines must provide adequate data informing the potential risk of vaccine-associated Enhanced Respiratory Disease (ERD).

Hindustan Times - your fastest source for breaking news! Read now.

Also Read | 30 Covid-19 vaccine candidates under development, Govt informs Lok Sabha

DCGI has also asked the pharma companies to keep pregnant women and women of childbearing potential in mind as they are developing the vaccines. Safety assessments throughout clinical development and all pregnancies in study participants for which the date of conception is prior to vaccination or within 30 days after vaccination should be followed for pregnancy outcomes, including pregnancy loss, stillbirth, and congenital anomalies, it said.

Fifty per cent efficacy is a global standard as WHO, in its guidelines, mentioned 50 per cent efficacy fro a vaccine to be accepted and pharma giants like Astrazeneca, too, in its trial blueprint asserted that the company is working towards a vaccine with 50 per cent efficacy. “For respiratory viruses, we never get 100 per cent efficacy. We are aiming for 100 per cent efficacy but may get 50-100 per cent,” Dr Balram Bhargava, ICMR, Director-General said.

The DCGI has also asked pharma companies to present a final analysis plan before closing the trail database. “This should include any planned interim analyses, which should be adequately addressed in terms of purpose, timing, and any statistical adjustments required,” the guideline said.

“If a trial fails to meet the predefined criteria for superiority and/or non-inferiority with respect to any of the antigenic components, the possible reasons for the result and the clinical implications of it should be carefully considered before proceeding with clinical development or licensure,” DCGI said.

(With ANI inputs)

Unveiling 'Elections 2024: The Big Picture', a fresh segment in HT's talk show 'The Interview with Kumkum Chadha', where leaders across the political spectrum discuss the upcoming general elections. Watch Now!

Get Current Updates on India News, Rajya Sabha Election 2024 Live, Gaganyaan Mission Astronauts along with Latest News and Top Headlines from India and around the world
SHARE THIS ARTICLE ON
Share this article
SHARE
Story Saved
Live Score
OPEN APP
Saved Articles
Following
My Reads
Sign out
New Delhi 0C
Tuesday, February 27, 2024
Start 14 Days Free Trial Subscribe Now
Follow Us On